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Abstract 
Background 
Herbal marijuana alternatives (HMA), legal plant products adulterated with synthetic 
cannabinoid receptor agonists, represent a growing public health concern.  Only a few 
case reports describe HMA and synthetic cannabinoid’s clinical toxicity.  We describe an 
outbreak of HMA abuse primarily in the Midwest, the clinical presentation of HMA 
toxicity, and clinical and forensic testing.  
Methods 
During the course of ongoing surveillance for emerging drugs of abuse between 
November 2009 and August 2010, we retrospectively and prospectively identified a 
convenience sample comprising 81 cases of abuse of HMA products.  Subject 
demographics, vital signs, lab results and urine were obtained (when available) and tested 
via gas chromatography mass spectrometry (GCMS) analysis.  Samples of HMAs and 
synthetic cannabinoids were also analyzed via GCMS. 
Results 
HMA users were predominantly young males who inhaled HMAs.  Analysis of their 
urine detected synthetic cannabinoid parent compound in one subject.  GCMS analysis of 
synthetic cannabinoids established a reference library that confirmed the presence of 
synthetic cannabinoids in sampled HMA products. 
Conclusion: 
HMA products were available in head shops, gas stations, and via the Internet.  We have 
confirmed the presence of synthetic cannabinoids in these HMA products.  The 
 vii 
tachycardia, hypertension, agitation, anxiety, vomiting and hallucinations observed in this 
convenience sample are not readily explained by the presence of synthetic cannabinoids 
acting on CB1 and CB2 receptors.  Further research must be done on HMA products and 
their abusers. 
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CHAPTER I: Introduction 
History of HMAs 
Herbal marijuana alternatives (HMAs) are legally available drugs of abuse growing in 
popularity across the U.S. and abroad.  While cleverly labeled not for human 
consumption, HMAs are available on-line and in specialty shops as legal alternatives to 
marijuana that allegedly produce a similar clinical effect but are not detectable by 
traditional marijuana screening tests.   
 
Beginning in 2004, European authorities recognized HMA abuse on the Internet.1  In 
2009, the European Monitoring Centre for Drugs and Drug Addiction released a report 
identifying the brand-named HMA Spice as a combination of plant material and 
intentionally added synthetic cannabinoid research chemicals.2   Prior to this report, there 
was a paucity of data available describing the toxicity of the herbs or synthetic 
cannabinoids present in HMAs.3  Initial synthetic cannabinoid pharmacokinetic and 
animal data did not easily translate into anticipated clinical effects in humans.4-7   
 
Subsequently, German scientists working in concert with InterPol performed both 
forensic Gas Chromatography-Mass Spectrometry (GC-MS) and Liquid 
Chromatography-Mass Spectrometry (LC-MS/MS) testing on multiple HMA samples as 
well as self-experiments smoking the HMA products.8   These scientists substantiated the 
belief that HMAs were not detectable via drug tests by demonstrating that neither the 
HMA products themselves, nor human urine samples obtained from HMA exposed 
 2 
volunteers, demonstrated cross-reactivity with existing marijuana (i.e. ∆9-
tetrahydrocannabinol (∆9-THC)) immunoassays.8  Researchers discovered that some (but 
not all) HMA samples contained JWH-018, oleamide, and CP 47,497-analogue.8  Never 
tested in humans, JWH-018 and other JWH-compounds are non-naturally occurring 
aminoalkylindoles designed in the 1990’s and studied by John W. Huffman (an organic 
chemist at Clemson University) to better understand CB receptors.9, 10  While oleamide is 
a naturally occurring fatty acid known to interact with endogenous cannabinoid receptors 
(CBs) in a manner similar to that of anandamide, CP 47,497 is cannabimimetic 
cyclohexylphenol created by Pfizer in the 1970’s.11, 12,2  The location and manufacturing 
details of synthetic cannabinoids remains purely speculative. 
 
For decades, both basic science researchers and pharmaceutical companies have designed 
hundreds of synthetic cannabinoids in the quest for better understanding of CB receptor-
ligand binding relationships, and discovering a chemical compound with the therapeutic 
properties of ∆9-THC, without its psychotropic effects.13  Most synthetic cannabinoids 
had not been tested in humans, so their potentially toxic effects were unknown before the 
current epidemic. 
 
Japanese, U.S., and U.K. investigators subsequently identified the following synthetic 
cannabinoids in seized HMA samples: HU-210 (so named for Hebrew University where 
it was created in the 1960’s), JWH-073, JWH-250, and JWH-398 (TABLE 1.1).2, 14-18 
While little was known about the potential health risks associated with these synthetically  
 3 
        
 
  
 
 
  
 
 
 
  
  
  
  
 
 
 
 
 
 
 
  
  
 
 
 
 
 
  
    
      
  
   
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 4 
derived substances, the growing popularity of HMA products and the possibility of 
toxicity lead many European countries to ultimately ban the brand-named Spice product 
and other similar HMAs. 
 
Coincident with the European ban of HMAs, the first cases of HMA abuse in the U.S. 
became recognized by the DEA.2  Reports associated HMAs with dry mouth, quickened 
pulse, and agitation for up to 6 hours; fatalities were also reported.19-21  An 18 year old 
man in the Midwest took his own life by shooting himself  in 2010, after becoming 
agitated from smoking K2.22  This growing public health threat in the Midwest 
inexplicably began as a geographic anomaly that ultimately spread to other parts of the 
country.23  In the spring of 2011, the following synthetic cannabinoids fell under 
schedule-1 restriction by the DEA: JWH-018, JWH-073, JWH-200, CP 47-497, and CP 
47-497 C8 homologue.24  Currently, HMAs are still available as legal drugs of abuse, not 
containing any illegal substances.25 
 
Pharmacology of Cannabinoid Receptors 
Synthetic cannabinoids can be divided into the following 7 structural groups: 1) classical 
cannabinoids (HU-210), 2) cyclohexylphenols (CP 47,497), phenylacetylindoles (JWH-
250), 4) naphthylmethylindenes, 5) naphthoylpyrrols, 6) naphthylmethylindoles, and 7) 
naphthoylindoles (JWH-018, JWH-073).12, 26   Cannabinoid receptors are those that 
interact with cannabinoid-like drugs, including phytobiotics (∆9-THC), synthetic 
cannabinoids (JWH-compounds), or endogenous cannabinoids (anandamide).27, 28  
 5 
Despite these synthetic cannabinoids’ structural analogy to ∆9-THC, these compounds 
are agonists at CBs.28  The two types of CB receptors (CB1 and CB2) are G-protein 
coupled receptors located primarily in the central nervous system (e.g. basal ganglia, 
hippocampus, cortex and cerebellum) and peripheral tissues (e.g. immune cells, blood 
cells, and spleen) respectively.27, 29-32   CB1 receptors have been localized to presynaptic 
GABA neurons, and the CB2 receptors on immune cells could affect cytokine release and 
cell migration.7, 29, 33, 34  The peripheral CB2 receptor effect is the likely root of ∆9-THC’s 
anti-inflammatory effects. 
 
As mentioned previously, the ongoing pursuit of therapeutic cannabinoid discovery 
involves developing a CB2 receptor-specific cannabinoid that exhibits minimal 
interaction with central CB1 central receptors.
35 However, there is growing evidence to 
suggest that CB2 receptors may also be present in the CNS.
4   Because synthetic 
cannabinoids have much greater binding affinities for CB receptors than ∆9-THC, one 
understands why HMA manufacturers might infer strong marijuana-like effects.36  
 
Evidence for Herbal Effects 
Of the herbal constituents identified in certain HMAs (TABLE 1.2), there is, at best, 
anecdotal and historical evidence to support psychotropic or marijuana-like effects.2, 25  
For instance, the Nymphaeaceae family of water lilies have been depicted on the tombs 
of Ramses II, Amenhotep I, and Tutankhamun and may have been used as narcotics in 
religious ceremonies.3  The most well known herb is a South African plant called Wild  
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Dagga.  While Wild Dagga is abused for its alleged euphoric effects, no pharmacologic 
data exists to support this alleged effect.  The scientific data demonstrates anti-
inflammatory, analgesic, and hypoglycemic effects in mice and rats.37   Although makers 
of HMAs may also be intimating psychotropic effects via Comfrey, the pyrrolizidine 
alkaloids found in Comfrey plant material are also known to be hepatotoxic.38, 39   
Furthermore, there is evidence to support Rosehip use as an anti-inflammatory agent for 
the treatment of osteoarthritis; there is no strong mechanistic evidence to support 
cannabimimetic effects.40  Neem leaf extract has demonstrated anti-inflammatory and 
possibly cancer-treating effects in vitro.41 
 
Specific Aims 
At the time of this study, K2 was not well understood.  It was our hypothesis that K2 was 
a brand of HMA (renamed from Spice after it had been recently banned in Europe), and 
that it may contain synthetic cannabinoids.  The primary aim of this study was to identify 
signs and symptoms associated with self-identified HMA abuse.  Secondary aims 
included 1) testing HMAs to confirm the presence of synthetic cannabinoids (or other 
adulterants); 2) testing synthetic cannabinoids to see if they cross reacted with the drug of 
abuse immunoassay for marijuana; 3) testing HMA abuser’s urine for presence of 
synthetic cannabinoids; and 4) to develop an effective means of capturing real-time data 
on emerging drugs of abuse (like HMAs). 
 8 
CHAPTER II: Methods 
Study design and setting 
This was a multi-center collaborative effort involving ongoing epidemiological 
surveillance for emerging drugs of abuse between November 2009 and August 2010.  
Initially, we identified a “signal” comprising 81 cases of abuse of HMA products.  In 
these cases, there appeared to be a shared commonality of agitation, tachycardia and 
hypertension.  After an investigation revealed additional cases in Missouri, Kansas, 
Georgia and Massachusetts, and after consultation with the Centers for Disease Control 
(CDC), we developed case definition criteria that included patient-identified exposure to 
HMAs. We used that criteria to both retrospectively and prospectively identify cases of 
HMA exposure through the Missouri Poison Control Center, Georgia Poison Control 
Center, and the University of Massachusetts Medical Toxicology consultation service.  
Cases presented as 1) phone-calls to Poison Control Centers, 2) Emergency Department 
visits, or 3) in-hospital Medical Toxicology consultations. When available, data was 
collected regarding subject demographics, vital signs, physical exam findings, symptoms, 
and laboratory testing (such as qualitative urine immunoassays for typical drug of abuse 
like opiates, benzodiazepines, marijuana and cocaine).   
 
Laboratory Testing 
Synthetic Cannabinoid Laboratory Testing via Immunoassay   
Prior to DEA scheduling of certain synthetic cannabinoids, we acquired samples of the 
synthetic cannabinoids JWH-015, JWH-018, JWH-073 and JWH-200 (in the form of a 
 9 
white powder) via Internet vendors for $20/100mg.  We spiked human urine control 
samples with these samples of synthetic cannabinoid powders and tested them via the 
Microgenics Corporation qualitative drug of abuse immunoassay to see if they generated 
a positive cannabinoid result.  
 
Synthetic Cannabinoid Laboratory Testing via GC-MS 
We used GC-MS to test JWH-015, JWH-018, JWH-073 and JWH-200 via a single step 
liquid extraction at pH 8–10 with ammonium hydroxide and dichloromethane. The 
extract was reconstituted with ethyl acetate. A sample was injected on Agilent 5973 GC-
MS using chemstation software and an HP1 12 m capillary column. Chlorimipramine 
was the internal standard.  Subsequently, a comprehensive list of synthetic cannabinoids 
was analyzed via similar GC-MS analysis and their mass spectra were entered into a GC-
MS library as reference standards (against which future urine tests would be 
analyzed)(TABLE 2.1).   
 
HMA Forensic Testing 
Prior to local and federal regulations on HMA products, we acquired multiple samples of 
K2 from Internet vendors and completed forensic GC-MS testing at the St. Louis forensic 
laboratories (Figures 2.1-2.3).  Four milliliters of forensic samples were extracted with a 
9:1, hexane: ethylacetate mixture.  Deuterated internal standards were used.  The first 
standard was an alkaline extraction and then an acid back extraction. The solvent was  
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 14 
evaporated and reconstituted with the derivatizing agent BSTFA, heated for 15 minutes at 
100 degrees, and then 2 microliters were injected.  
 
Human Urine Sample Laboratory Testing 
After obtaining IRB approval (or waiver) and subjects’ informed consent, we obtained 22 
urine samples from self-identified HMA abusers presenting to Emergency Departments 
for complaints directly self-attributed to HMA exposures.  Each urine sample was de-
identified and stored in a plastic specimen container before being sent at either room 
temperature or frozen on dry ice and mailed (via Federal Express ® overnight shipping) 
to the University of Massachusetts toxicology laboratory or the St. Louis toxicology 
laboratory, for independent confirmatory testing.   After arriving in each laboratory, the 
urine sample was tested at room-air temperature (or thawed to room-air temperature 
when appropriate) and analyzed via GC-MS analysis for known xenobiotics and illicit 
drugs (including the synthetic cannabinoids). 
 
Creation of Toxicology Database 
With IRB approval, we used the University of Massachusetts information technology 
support structure to create a toxicology database (TOXIDARE) in order to facilitate 
prospective data collection efforts and further research on emerging drugs of abuse in 
cases presenting to the UMass Medical Toxicology Consultation service.  This Internet-
based database was created using REDCap © (Research Electronic Data Capture) 
technology, based out of Vanderbilt University.42  Access to data entry was created for 
 15 
Emergency Medicine residents during their Toxicology rotation, Medical Toxicology 
fellows and attending physicians.  
 
Primary Data Analysis and Outcome Measures 
Data analysis of patient information was performed via descriptive statistics including 
ranges, means, medians and modes calculated with Microsoft Office Excel, 2008 ©.  
Laboratory data analysis was performed by methods previously described in this study. 
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CHAPTER III: Clinical Results 
Characteristics of Study Subjects 
We identified a total of 81 cases of HMA abuse between November 2009 and August 
2010 who presented to Poison Control Centers via phone call, EMS personnel, 
Emergency Departments, or Medical Toxicology services.  Patients were primarily young 
males (the youngest subject was 12 years old) who smoked or inhaled HMA (TABLE 
3.1).  When presenting to a health care provider, subjects commonly had elevated heart 
rates and blood pressures. The most commonly reported symptoms were anxiety, 
confusion and agitation. Fifteen patients reported nausea or vomiting.  There were 3 
reported seizures, and an additional subject (who did not seize) called the Missouri 
Poison Control Center because he was concerned after his friend “seized” after smoking 
the same K2 product.  Nine subjects reported visual hallucinations. Reportedly within one 
hour of K2 exposure, one subject committed suicide with a firearm after reporting 
paranoia, thinking he was “in hell” according to non-medical provider accounts.  Subjects 
most commonly required 4-24 hours of observation in the ED, with 6 subjects requiring 
hospital floor admission for up to 3 days.  One individual required the administration of 
BIPAP and ultimate ICU admission for respiratory difficulty (TABLE 3.2). 
 
In this surveillance study, subjects most frequently purchased HMAs from local head 
shops or gas stations, and the most frequently reported HMAs were K2, Spice, and K2 
Summit (TABLE 3.3). 
 17 
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Laboratory Findings 
Of the serum chemistry laboratory results obtained, there were 3 subjects with K+ values 
< 2.8 mEquiv/L; one subject had a K+ value of 1.7 mEquiv/L (TABLE 3.4).    Urine 
immunoassay testing ordered during hospital evaluation revealed positive THC results in 
5 subjects; of these, one individual admitted to smoking marijuana as well as K2. 
 
Urine GC-MS Testing 
Of the 22 subjects who volunteered their urine for research testing, only one subject’s 
urine returned a positive result for a synthetic cannabinoid (JWH-018).  Testing 
demonstrated the presence of various xenobiotics, most commonly caffeine and nicotine 
(TABLE 3.5). 
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CHAPTER IV: Forensic Laboratory Results 
Synthetic Cannabinoid Testing Via Urine Immunoassay 
After adding samples of JWH-015, JWH-018, JWH-073 and JWH-200 to control human 
urine specimens, we ran the Microgenics EMIT immunoassay test that detects ∆9-THC.  
We found that none of these pure JWH-compounds generated a positive immunoassay 
result for THC. 
 
Synthetic Cannabinoid Evaluation via GC-MS 
We performed GC-MS analysis of 18 synthetic cannabinoids (TABLE 2.1).  Mass 
spectra results were available for each of these compounds, and they were each entered 
into the GC-MS library, against which each subject’s volunteered urine was tested. 
 
Forensic Testing of HMA Sample 
Through forensic GC-MS analysis of multiple acquired samples of HMAs, we confirmed 
the presence of the following synthetic cannabinoids: RCS4, JWH-018, JWH-73, JWH-
081, and JWH-122. 
 24 
Chapter V: Conclusion 
Coincident with the Midwestern U.S. HMA epidemic that broke out during the Spring of 
2010, we confirmed the presence of synthetic cannabinoids in HMAs.  We also 
confirmed the presence of synthetic cannabinoids in one subject’s volunteered urine 
sample via GC-MS analysis.   Subjects with untoward symptoms resulting from self-
identified HMA inhalation most commonly manifested tachycardia, hypertension, 
agitation, anxiety and vomiting.  We identified cases of seizure and suicide associated 
with HMA exposure.  
 
Synthetic cannabinoids likely present in HMAs did not trigger a positive THC result by 
urine immunoassay testing directed at ∆9-THC.  This illustrates one of the likely reasons 
for HMAs’ popularity, which is avoidance of drug detection. 
 25 
Chapter VI:  Strengths and Limitations 
Strengths 
The present study had several strengths, which included prospective data collection on a 
novel emerging drug of abuse.  At the time of the study, there were only isolated case 
reports of HMA abuse and associated clinical symptoms.  The multi-center and 
multidisciplinary effort involving Poison Control Specialists, physicians and laboratory 
experts in forensic analysis maximized the number of cases and allowed for confirmatory 
testing.   
 
Limitations 
Missing Data 
There were several limitations that must be kept in mind in interpreting the present 
results.  There was a significant amount of missing data in this investigation.  Data 
collection took place contemporaneously with the occurrence of the HMA epidemic, 
primarily located in the Midwest.   Because of the need to collect as much information as 
possible, a data collection template was provided to Poison Control Center specialists in 
Missouri, Georgia, Kansas and toxicologists at the University of Massachusetts.  This 
multistate collaborative effort was needed in order to maximize the number of cases.  
Despite extensive educational efforts and requests to collect relevant subject details, it 
was remarkably difficult to collect information.  Many subject encounters took place over 
the phone, and subjects were not willing to participate in a lengthy data collection 
interview.  When subjects presented to a health care facility, Poison Control Center 
 26 
specialists again depended on the ability and willingness of the often-busy practicing 
physician or nurses in the Emergency Department.  
 
Vital sign and laboratory information was often collected only one time during a subjects 
hospital stay.  Depending on when vital signs, physical exams and laboratory testing were 
completed in relation to the time of exposure to HMAs, the results might have been 
considerably different. 
 
Selection Bias 
Because we did not know what the clinical effects of HMAs were prior to undertaking 
this study, it was not possible to develop a tailored data collection tool for confirmatory 
vital signs, laboratory findings, physical exam findings, or physical/psychiatric 
complaints.  Initially, we noted a common thread of agitation and sympathomimetic vital 
signs, so those details were part of our data collection instrument.  We did not initially 
note the presence of nausea or vomiting, therefore neither descriptor was a specific field 
on the data collection form.  Thus, the 15 cases of spontaneously reported nausea and 
vomiting likely under-represent the true incidence of vomiting in our study subjects. 
 
Inability to confirm subjects took HMAs 
Few subjects volunteered samples of their HMAs to health care personnel or law 
enforcement for confirmatory testing and analysis.   Therefore, it was not possible to 
validate our case-definition of self-identified HMA exposure with confirmatory lab 
 27 
testing.  Some data may, therefore, not represent HMA effects, but rather those of another 
drug of abuse. 
   
GC-MS urinalysis confirmed only 1 case of synthetic cannabinoid exposure 
First, it is possible that the subjects in this study were not exposed to synthetic 
cannabinoids.  Also, parent compounds of synthetic cannabinoids may not be stable or 
have a sufficient t1/2 to allow for detection hours after HMA exposure.  Too much time 
may have elapsed between 1) HMA exposure and urine sample collection, or 2) urine 
collection and toxicology testing.  It was not possible to determine how much time 
elapsed between exposure to HMAs and urine collection.  Synthetic cannabinoid parent 
compounds may also not be stable for transfer at freezing temperatures.  It was also 
possible (as has been suggested by other authors) that better synthetic cannabinoid 
detection in urine would come via testing for metabolites.43   
 
HMAs changing contents  
Although we tested for the most likely and available synthetic compounds, as identified 
by existing evidence at the time, it is possible that the subjects in this study were exposed 
to HMAs containing synthetic cannabinoids not accounted for by the 18 synthetic 
cannabinoids in our GC-MS library. 
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Chapter VII: Discussion 
Subsequent to the completion of this study, researchers have been able to detect synthetic 
cannabinoid metabolites in human urine via GC-MS testing.43, 44  If we conducted a 
similar study again with HMAs and HMA abusers, we would direct our urine testing at 
previously identified and possibly novel metabolites of synthetic cannabinoids known to 
contaminate HMAs.  However, due to the DEA listing many synthetic cannabinoids as 
schedule 1 substances, the ability to conduct such research has been significantly 
impaired.   
 
It is difficult to explain the seemingly sympathomimetic vital sign and physical exam 
abnormalities that appeared in the subjects in our surveillance study.  Delta-9-THC may 
be associated with psychosis, but it has been associated with both bradycardia and 
tachycardia.45-47   Moreover, the synthetic cannabinoid dronabinol is an FDA approved 
pharmacotherapy for often protracted vomiting secondary to chemotherapy.48  Therefore, 
the vomiting seen in our subject population would not be a symptom predicted to result 
from a synthetic cannabinoid interacting with CB receptors similarly to ∆9-THC.   
 
We considered the possibility of stimulants (and not synthetic cannabinoids) causing the 
symptoms seen in our subjects.  However, our GC-MS analysis would have likely been 
able to detect typical stimulants (like amphetamines and other phenylalanine-based 
xenobiotics), and it only did so in 2 of our subjects.  It is important to note that 
mephedrone was quite popular in Europe, and Bath Salts were beginning their rapid rise 
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to popularity around the time of the HMA epidemic.  Mephedrone is 4-
methylmethcathinone, which is a synthetic stimulant derived from cathinone – a 
substance found in the plant Khat.49  Bath Salts ultimately proved to contain 
sympathomimetics  (e.g. MDPV, amphetamines and cathinone-derivatives), which were 
confirmed to be present in seized samples of Bath Salts by law-enforcement.50  While 
unable to detect MDPV or certain cathinones at the time of the present study, our GC-MS 
library was able to detect amphetamines and mephedrone.  We did not detect 
mephedrone.  Researchers have subsequently described urinalysis testing that would 
easily allow for stimulants like mephedrone and MDPV that we would utilize for further 
observational studies on emerging drugs of abuse.51 
 
Synthetic cannabinoids may cause sympathomimetic symptoms by reverse signaling 
disinhibition, via GABA inhibition (thus leaving unopposed excitatory glutamate).  The 
hallucinations seen by one of our subjects may be explained by synthetic cannabinoid’s 
association with serotonergic activity.52  Seizures may manifest as cataplexy, a 
phenomenon explained by Martin et al who demonstrated synthetic cannabinoid activity 
on dopaminergic D1 and D2 receptors.
53  There are other published case reports of 
seizures associated with synthetic cannabinoid exposure.54 
 
The REDCap © database we created designed to address many of the data-collection 
difficulties experienced in our study.  Prospective data collection for emerging drugs of 
abuse (with respect to vital signs, physical exam findings, symptoms and laboratory 
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findings) is difficult due to the nature of drug abuse and how patients present to the health 
care system.  Much of the access to drug-abusing patients comes via phone calls to 
Poison Control Centers.  Poison Control specialist’s jobs are to provide appropriate 
medical advice and direct patients to hospital care when appropriate.  Rigorous data 
collection for research purposes, as a goal, is not often compatible or possible in this 
environment.  Furthermore, the Poison Control Center database does not easily lend itself 
to research-quality data collection.  It is my hope than the creation of the UMass REDCap 
© database will allow for more meaningful prospective data collection for emerging 
drugs of abuse (like HMAs), in order to contribute to the medical literature and 
Emergency Medicine community in a more scientifically rigorous fashion.
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